Chromatography 13 Detection of speciated volatile nitrosamines in pharmaceuticals using GC-TEA
In the pharmaceutical industry, the safety of medications is a critical concern, particularly with the risk posed by nitrosamine contamination. Nitrosamines, such as N-Nitrosodimethylamine (NDMA), are carcinogenic compounds that may form during drug manufacturing under specific conditions. Addressing this challenge, Ellutia’s 800 series Thermal Energy Analyser (TEA) provides a sophisticated solution for the accurate analysis of volatile nitrosamines through Gas Chromatography coupled with Thermal Energy Analysis (GC-TEA).
Nitrosamines typically arise when an amine - often a secondary amine - reacts with nitrosating agents like nitrites, either under acidic conditions or at elevated temperatures during the manufacturing process. The identification and quantification of these contaminants are vital, as demonstrated by the NDMA findings in Ranitidine, a formerly widespread antacid that was revealed to form NDMA over time under standard storage conditions.
Under EU Regulation (EC) No 726/2004, which establishes acceptable limits for 27 different nitrosamines, pharmaceutical manufacturers are mandated to perform risk assessments and conduct regular testing for these compounds. This regulation ensures that all medications adhere to safety standards prior to reaching consumers.
The operation of the GC-TEA system by Ellutia involves separating nitrosamines within the GC column, followed by their elution into the Pyrolyser. Here, the nitrosamines decompose to release nitric oxide (NO), which is subsequently detected by the TEA after reacting with ozone. This sequence facilitates the precise quantification of the nitrosamines present.
To prepare pharmaceutical samples for analysis, a process involving methanol extraction, centrifugation, and filtration is employed. This preparation is essential for obtaining accurate and reliable results. Notably, the TEA by Ellutia is recognised for its sensitivity and specificity, which significantly reduce background noise and interference - common issues in the detection of nitrosamines.
Incorporating the GC-TEA system into pharmaceutical testing protocols provides a robust mechanism for adhering to safety regulations and safeguarding public health. By offering detailed and reliable methods for analysing volatile nitrosamines, Ellutia reinforces the pharmaceutical industry’s dedication to drug safety and efficacy.
For further insight into volatile nitrosamine analysis by GC-TEA, including a focus on Metformin, join Ellutia’s upcoming webinar on 22nd May. Their experts will discuss these topics and more.
Register now:
ilmt.co/PL/lvOn More information online:
ilmt.co/PL/1ANm
62525pr@reply-direct.com
GC Detector for Volatile Nitrosamines
Specific Detection Only see NNO compounds
No False Positives
Avoid false positives due to daughter ions, enhancing result integrity
High Sensitivity
Measures nitrosamines down to ppb levels
Gas Chromatograph to TEA technology redefines nitrosamine analysis by focusing exclusively on what matters... nitrosamines.
Register for our free Chromatography Solutions
GC - TEA webinar
https://bit.ly/GC-TEA
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148
